1
2
S. Pawar & P. Vavia
J Drug Target, Early Online: 1–12
2
4. Uchegbu IF. The biodistribution of novel 200 nm palmitoyl
muramic acid vesicles. Int J Pharm 1998;162:19–27.
References
1
.
.
Gottesman MM, Fojo T, Bates SE. Multidrug resistance in
cancer: role of ATP-dependent transporters. Nat Rev Cancer
25. Jianing Q, Ping Y, Fen H, et al. Nanoparticles with dextran/chitosan
shell and BSA/chitosan core—doxorubicin loading and delivery.
Int J Pharm 2010;393:176–84.
26. Brownlie A, Uchegbu IF, Schatzlein AG. PEI-based vesicle–
polymer hybrid gene delivery system with improved biocompati-
bility. Int J Pharm 2004;274:41–52.
2
002;2:48–58.
2
Si-Shen F, Shu C. Chemotherapeutic engineering: application and
further development of chemical engineering principles for chemo-
therapy of cancer and other diseases. Chem Eng Sci 2003;58:
4
087–114.
27. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for
cytotoxicity screening. Nat Protoc 2006;1:1112–16.
28. Rao MV, Atreyi M, Rajeswar MR. Fluorescence studies on
concanavalin-A. J Biosci 1984;6:823–8.
29. Froehlich P. Understanding the sensitivity specification of spectro-
fluorometers. Int Lab 1989;19:42–5.
30. Chipman DM, Grisaro V, Sharon N. The binding of oligosacchar-
ides containing N-acetylglucosamine and N-acetylmuramic acid to
lysozyme. The specificity of binding subsites. J Biol Chem 1967;
242:4388–94.
3
.
Pereverzeva E, Treschalin I, Bodyagin D, et al. Influence of
the formulation on the tolerance profile of nanoparticle-bound
doxorubicin in healthy rats: focus on cardio- and testicular toxicity.
Int J Pharm 2007;337:346–56.
Aarif YK, Peter PL, Thomas F, et al. Cardiotoxicity due to cancer
therapy. Cancer Heart 2011;38:253–9.
Moorthi CR, Manavalan K, Kathiresan K. Nanotherapeutics to
overcome conventional cancer chemotherapy limitations. J Pharm
Pharmaceut Sci 2011;14:67–77.
4
5
.
.
6
7
8
9
.
.
.
.
Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an
emerging treatment modality for cancer. Nat Rev Drug Discov
31. Wu G, Robertson DH, Brooks CL, Vieth M. Detailed analysis of
grid-based molecular docking: a case study of CDOCKER-A
CHARMm-based MD docking algorithm. J Comput Chem 2003;
24:1549–62.
32. Glide, version 5.8, Schr o¨ dinger, LLC, New York, NY; 2012.
33. Maestro, version 9.3, Schr o¨ dinger, LLC, New York, NY; 2012.
34. Okimoto N, Futatsugi N, Fuji H, et al. High-performance drug
discovery: computational screening by combining docking and
molecular dynamics simulations. PLoS Comput Biol 2009;5:1–12.
35. Kandasamy R, Veintramuthu S. Formulation and optimization of
zidovudine niosomes. AAPS PharmSciTech 2010;11:1119–27.
36. You HB, Kinam P. Targeted drug delivery to tumors: myths, reality
and possibility. J Control Release 2011;153:198–205.
2
008;7:771–82.
Yogeshkumar M, Marilena L, Alexander MS. Liposomes and
nanoparticles: nanosized vehicles for drug delivery in cancer.
Trends Pharmacol Sci 2009;30:592–9.
Xiaowei D, Russell JM. Nanomedicinal strategies to treat multi-
drug-resistant tumors: current progress. Nanomedicine (Lond)
2
010;5:597–615.
Frank G, Rohit K, Andrew W, et al. Targeted nanoparticles for
cancer therapy. Nano Today 2007;2:14–21.
1
0. Lara SJ, Lilian EV, Sunita Y, Mansoor MA. Multi-functional
nanocarriers to overcome tumor drug resistance. Cancer Treat Rev
2
008;34:592–602.
37. Sahin NO. Niosomes as nanocarrier systems. In: Mozafari MR, ed.
Nanomaterials and nanosystems for biomedical applications.
Netherlands: Springer; 2007:67–81.
1
1
1. Ruth D. Polymer conjugates as anticancer nanomedicines. Nat Rev
Cancer 2006;6:688–701.
2. Chris O, Wouter B, Mariska B, et al. Polymeric micelles in
anticancer therapy: targeting, imaging and triggered release. Pharm
Res 2010;27:2569–89.
3. Lilian EV, Mansoor MA. Multi-functional polymeric nanoparticles
for tumour-targeted drug delivery. Expert Opin Drug Deliv 2006;3:
38. Al-Hamidi H, Edwards AA, Mohammad MA, Nokhodchi A. To
enhance dissolution rate of poorly water-soluble drugs: glucosa-
mine hydrochloride as a potential carrier in solid dispersion
formulations. Colloids Surf B 2010;76:170–8.
39. US2011/0243851. Glucose PEG conjugate for reducing glucose
transport into the cell.
40. Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of
facilitative glucose transporter genes in human cancer. Biochem
Biophys Res Commun 1990;170:223–30.
41. Schlick KH, Lange CK, Gillispie GD, Cloninger MJ.
Characterization of protein aggregation via intrinsic fluorescence
lifetime. J Am Chem Soc 2009;131:16608–9.
42. Sha Z, Shiladitya B, William C, et al. Leucine–aspartic acid–valine
sequence as targeting ligand and drug carrier for doxorubicin
delivery to melanoma cells: in vitro cellular uptake and cytotoxicity
studies. Pharmaceut Res 2009;26:2578–87.
43. Dorit G, Aviva TH, Dina T, et al. Nuclear delivery of doxorubicin
via folate-targeted liposomes with bypass of multidrug-resistance
efflux pump. Clin Cancer Res 2000;6:1949–57.
44. Eksborg S. Extraction of daunorubicin and doxorubicin and their
hydroxyl metabolites: self-association in aqueous solution. J Pharm
Sci 1978;67:782–5.
1
1
1
2
05–16.
4. Darandale SS, Vavia PR. Cyclodextrin-based nanosponges of
curcumin: formulation and physicochemical characterization.
J Incl phenom macrocycl Chem 2013;75:315–22.
5. Uchegbu IF, Double JA, Kelland LR, et al. The activity of
doxorubicin niosomes against an ovarian cancer cell line and three
in vivo mouse tumour models. J Drug Target 1996;3:399–409.
6. John WP. Liposome-based drug delivery in breast cancer treatment.
Breast Cancer Res 2002;4:95–9.
1
1
7. Carlotta M, Donatella P, Christian C, et al. Non-ionic surfactant
vesicles in pulmonary glucocorticoid delivery: characterization and
interaction with human lung fibroblasts. J Control Release 2010;
1
47:127–35.
1
8. Marzio LD, Marianecci C, Cinque B, et al. pH-sensitive non-
phospholipid vesicle and macrophage-like cells: binding, uptake
and endocytotic pathway. Biochim Biophys Acta 2008;1778:
2
749–56.
1
2
9. Jain CP, Vyas SP. Preparation and characterization of niosomes
containing rifampicin for lung targeting, J Microencapsul 1995;12:
45. Mennozi M, Valentini L, Vannini E, Arcamone F. Self-association
of doxorubicin and related compounds in aqueous solution. J Pharm
Sci 1984;73:766–70.
46. Takafumi M, Eriko T, Yuji K, et al. FDG uptake and glucose
transporter subtype expressions in experimental tumor and inflam-
mation models. J Nucl Med 2001;42:1551–5.
4
01–7.
0. Pawar SK, Badhwar AJ, Kharas F, et al. Design, synthesis and
evaluation of N-acetyl glucosamine (NAG)-PEG-doxorubicin tar-
geted conjugates for anticancer delivery. Int J Pharm 2012;436:
1
83–93.
47. Raffaele C, Agnese V, Cristina R, et al. Expression analysis of
facilitative glucose transporters (GLUTs) in human thyroid carcin-
oma cell lines and primary tumors. Mol Cell Endocrinol 2008;291:
57–62.
48. Thomas AH, Robert BM, Richard AF, et al. Glide: a new approach
for rapid, accurate docking and scoring. 2. Enrichment factors in
database screening. J Med Chem 2004;47:1750–9.
49. Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach
for rapid, accurate docking and scoring. 1. Method and assessment
of docking accuracy. J Med Chem 2004;47:1739–49.
2
2
2
1. Johanna C, Christiane BH, Jacques P. Tumour hypoxia induces a
metabolic shift causing acidosis: a common feature in cancer. J Cell
Mol Med 2010;14:771–94.
2. Warburg O, Posener K, Negelein E. The metabolism of the
carcinoma cell. In: Warburg O, ed. The metabolism of tumors.
New York: Richard Smith, Inc.; 1931:29–169.
3. Taizo Y, Yutaka S, Hirofumi F, et al. Over-expression of facilitative
glucose transporter genes in human cancer. Biochem Biophys Res
Commun 1990;170:223–30.